Evogene Ltd. EVGN

Company Overview

Evogene Ltd. is an Israeli computational biology and biotechnology company focused on developing life-science products through the application of artificial intelligence, computational predictive biology, and big data technologies. The company operates across the agriculture and human health sectors, using its proprietary Computational Predictive Biology (CPB) platform to identify and optimize biological components such as microbes, small molecules, and genetic elements. Evogene’s activities span crop protection, seed trait development, ag-biologicals, and medical cannabis-related therapeutics and product development.

The company’s business model centers on creating and commercializing technologies through subsidiaries and strategic collaborations. Its primary revenue drivers have historically included research collaborations, licensing arrangements, milestone payments, and technology commercialization. Evogene was founded in 1999 as a division of Compugen and later became an independent publicly traded company listed on Nasdaq under the ticker EVGN. Over time, the company evolved from a crop genetics-focused enterprise into a broader computational biology platform company serving multiple biotechnology verticals.

Business Operations

Evogene conducts operations primarily through several specialized subsidiaries and business platforms. These include Lavie Bio Ltd., focused on microbiome-based agricultural biologicals; Canonic Ltd., focused on medical cannabis products and genetics; Biomica Ltd., engaged in microbiome-based therapeutics for human health; and AgPlenus Ltd., which develops novel crop protection products including herbicides. The company also previously operated Casterra Ag Ltd., which focused on castor seed cultivation for industrial oil applications. Revenue generation is tied to collaborative agreements, licensing, research services, product development arrangements, and in some cases equity investments and milestone-based partnerships.

Evogene’s technology infrastructure is built around its CPB platform, which integrates artificial intelligence, machine learning, genomics, microbiome analytics, and computational chemistry. The company operates primarily from Israel while maintaining partnerships and commercial relationships internationally. Strategic collaborations have included multinational agricultural and biotechnology companies, with partnerships historically involving organizations such as Bayer and Corteva in various research and development contexts. The company’s operations combine in-house computational capabilities with subsidiary-led product commercialization strategies.

Strategic Position & Investments

Evogene’s strategic direction emphasizes leveraging computational biology to accelerate discovery timelines and improve probability of success in biotechnology development. The company has focused investments on artificial intelligence-driven biology platforms capable of identifying novel compounds, microbial candidates, and genetic traits across agricultural and medical applications. Its growth strategy has centered on developing independent subsidiaries capable of attracting strategic investors, partnerships, and external financing while retaining access to Evogene’s computational platform.

Major investments and strategic initiatives have included continued development of Biomica Ltd. for microbiome-based immunotherapy and gastrointestinal therapeutics, expansion of Lavie Bio Ltd. in biological crop protection and yield enhancement products, and advancement of AgPlenus Ltd. herbicide discovery programs. Evogene has also pursued commercialization opportunities in medical cannabis through Canonic Ltd., including genetically stabilized cannabis cultivars and consumer product initiatives. The company positions itself within emerging sectors such as AI-enabled drug discovery, agricultural biologicals, sustainable crop protection, and microbiome therapeutics.

Geographic Footprint

Evogene is headquartered in Rehovot, Israel, where it maintains its principal research and development operations. The company’s activities are primarily concentrated in Israel, though its subsidiaries and collaborations extend into North America, Europe, and selected international agricultural markets. Through strategic partnerships and commercial relationships, Evogene participates in global biotechnology and agricultural ecosystems despite its relatively modest corporate scale.

The company’s market presence is strongest in sectors tied to agricultural biotechnology and computational biology innovation. Its subsidiaries have pursued commercial and research collaborations with organizations operating in the United States, Europe, and other global markets. International influence is driven less by direct large-scale commercial operations and more by technology licensing, collaborative development agreements, and participation in multinational biotechnology initiatives.

Leadership & Governance

Evogene’s leadership structure combines expertise in biotechnology, computational biology, agriculture, and finance. The company has emphasized a technology-driven management philosophy focused on integrating artificial intelligence and predictive biology into product discovery and commercialization processes. Corporate governance oversight is provided through its board of directors and executive leadership team in accordance with requirements applicable to Nasdaq-listed companies and Israeli corporate governance standards.

Key executives include:

• Ofer Haviv – President and Chief Executive Officer
• Shai Almog – Chief Financial Officer
• Yaniv Maor – Chief Executive Officer of Biomica Ltd.
• Ilan Sela – Chief Executive Officer of Lavie Bio Ltd.
• Ido Margalit – Chief Executive Officer of Canonic Ltd.
• Gil Bochkovsky – Chief Executive Officer of AgPlenus Ltd.

The company’s leadership strategy has consistently emphasized building independent subsidiary platforms around Evogene’s core computational technologies while pursuing strategic collaborations and external investment opportunities to support long-term commercialization efforts.